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Abstract
We present the case of including sacubitril/valsartan in an octogenarian patient with 
congestive heart failure as a part of the outpatient cardiac rehabilitation program. The case 
shows that apart from hospital use, it is worth considering including this drug during an 
outpatient cardiac rehabilitation program, because in such conditions the patient is in frequent 
contact with the treatment center, so his health status may be assessed almost every day.
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Introduction
Sacubitril/valsartan (Entresto™) is the only angiotensin receptor neprilysin inhibitor (ARNI) 
drug available. Sacubitril is a neprilysin inhibitor that increases the amount of natriuretic 
peptides in the body, resulting in, among other things:
— increased diuresis and urinary sodium excretion;
— blockade of renin and aldosterone release, reduction of sympathetic nervous system 
activity;
— vasodilatation, inhibition of pathological myocardial remodeling.
The second component, valsartan, dilates blood vessels and inhibits adverse signaling 
pathways (inflammation, fibrosis, apoptosis) by blocking the receptor for angiotensin II. To 
date, sacubitril/valsartan has been indicated for patients who tolerate angiotensin-converting 
enzyme inhibitor (ACEI)/angiotensin II receptor antagonist/angiotensin receptor blocker 
(ARB) well, with a left ventricular ejection fraction ≤ 35% and present with symptoms of 
New York Heart Association (NYHA)class II–III severity, despite administration of 
ACEI/ARB and a beta-blocker as well as aldosterone antagonist at optimal doses. However, 
according to the latest recommendations [1] of the American College of Cardiology (ACC), it 
can be used from the beginning of the therapy as a first-line drug.
Case report
We present a case of an 86-year-old patient with chronic heart failure with reduced ejection 
fraction (HFrEF) in NYHA class II, after hospitalization for exacerbation of heart failure 
symptoms, admitted to a cardiac rehabilitation day center for rehabilitation. At discharge from
the hospital, the patient was prescribed the following medications: acetylsalicylic acid 75 mg, 
atorvastatin 20 mg, perindopril 2.5 mg, pantoprazole 20 mg, bisoprolol 5 mg, eplerenone 25 
mg, amiodarone 200 mg, trimethazine 35 mg, rivaroxaban 15mg, and nitroglycerin 0.4 mg — 
for angina pain. The patient had undergone (stated how many years before the inclusion of 
sacubitril/valsartan) non-ST-elevation myocardial infarction (NSTEMI) (8 years), coronary 
artery bypass grafting (8 years), cryoablation for atrial flutter (8 years), and developed post-
amiodarone hypothyroidism after the inclusion of amiodarone — substitution of L-tyroxin 
50 micrograms was started (1 year) [2]. Echocardiography performed on admission showed 
enlargement of the heart, segmental left ventricular wall motion abnormalities with an 
ejection fraction (EF) of 30% (Table 1). Based on the initial electrocardiographic stress test 
performed on a treadmill according to the Bruce protocol (Table 2), the patient was qualified 
for exercise rehabilitation in the form of:
— endurance and interval training on a cycle ergometer;
— breathing and general fitness exercises;
— upper and lower limb resistance exercises on a workout station, stepper and elliptical 
trainer;
— marching.
Table1. Selected echocardiographic parameters before and after cardiac rehabilitation




Left ventricle [mm] 48/58 48/60
Left atrium [mm] 52 52


















Valvular stenosis, 5 mm vena 
contracta, no systolic pulmonary 
venous flow regurgitation
Valvular stenosis, 5 mm 
vena contracta, no systolic 
pulmonary venous flow 
regurgitation





Minor marginal valvular fibrosis 
without the restriction of mobility
Minor marginal valvular 
fibrosis without the 
restriction of mobility
Vmax [m/s] 1.2 1.2
Regurgitation Trace Trace
Tricuspid valve
No organic lesions No organic lesions
Vmax [m/s] 0.6 0.6
Regurgitation I I
sPAP [mm Hg] 35 35
Pulmonary valve No organic lesions No organic lesions
Vmax [m/s] 0.9 0.9
Regurgitation Trace Trace







Akinesis of the posterior wall, 
inferior wall, 1/2 basal septum; 
hypokinesis of 1/2 apical lateral 
wall and septum
Akinesis of the posterior 
wall, inferior wall, 1/2 basal
septum; hypokinesis of 1/2 
apical lateral wall and 
septum
Ejection fraction [%] 30 30
TAPSE [mm] 14 14
sPAP — systolic pulmonary arterial pressure; TAPSE — tricuspid annulus peak systolic 
excursion
Table 2. Results of selected tests before and after cardiac rehabilitation




NT-proBNP [pg/ml] 4159 3314
Stress test










Fatigue — 13 according to
Borg rating. Obtained heart
rate limit
Fatigue — 12 according to
Borg rating. Obtained heart
rate limit
Changes in the 
analyzed leads
RBBB + LBBB RBBB + LBBB
Retrosternal pain Absent Absent
Test result Clinically negative Clinically negative
eGFR — estimated glomerular filtration rate; CKD-EPI — Chronic Kidney Disease 
Epidemiology Collaboration NT-proBNP — N-terminal pro-B-type natriuretic 
peptide; RBBB — right bundle branch block; LBBB — left bundle branch block
Outpatient rehabilitation lasted for 2–4 hours a day Monday through Friday for 24 
sessions. In addition, the patient participated in an educational program on risk factors for 
cardiovascular disease, classes with a psychologist on stress management, and relaxation 
therapy. During the rehabilitation program, a decision was made to optimize HFrEF treatment 
and after discontinuing perindopril, sacubitril/valsartan was implemented, and rehabilitation 
was continued. The entire rehabilitation cycle was completed without complications, and the 
final stress test (Table 2) showed improvement in physical performance indices. This was not 
the patient's first participation in a cardiac rehabilitation program — the improvement or lack 
of change in exercise capacity expressed by metabolic equivalent (MET) in subsequent years 
is shown in Figure 1. It is noteworthy that the patient's physical capacity decreased over the 
years, and the penultimate cycle of improvement treatment (2017) failed to improve physical 
capacity parameters. In contrast, it improved after the last rehabilitation, during which 
sacubitril/valsartan therapy was included.
Figure 1. Change in achieved physical fitness in metabolic equivalents (METs) in subsequent 
years assessed before and after the cardiac rehabilitation program
Discussion
Sacubitril/valsartan is a drug that was included in 2016 by the European Society of 
Cardiology in its guidelines for the treatment of patients with heart failure and reduced 
ejection fraction. Since then, its use and efficacy have been documented through numerous 
randomized clinical trials [3, 4] that demonstrated that taking sacubitril/valsartan — compared
to ACEI/ARB therapy of patients with reduced ejection fraction — was associated with a 
lower risk of death (12–20%) and patient hospitalization (14–16%). Moreover, studies [5] 
show a positive effect of ARNI on cardiac parameters — functional improvement as 
determined by NYHA scale and reduction of mitral regurgitation severity. Including 
sacubitril/valsartan significantly reduces N-terminal pro-B-type natriuretic peptide (NT-
proBNP) levels, allows for lower doses of diuretics, and increases left ventricular ejection 
fraction.
However, the available literature lacks data showing the effect of ARNI on the 
effectiveness of cardiac rehabilitation. The case we discussed highlights the safety and 
efficacy of the drug in terms of improving physical performance. It is also noteworthy that 
positive treatment effects can be obtained in patients significantly older than the mean of 
patients included in the PARADIGM-HF study (63.8 ± 11.3 years) [6], which was the case in 
our report. According to the available data, a significant decrease in NT-proBNP was observed
in this patient [5]. Analyzing the results of the similar PARAGON-HF trial also demonstrated 
the positive impact of ARNI therapy in patients with preserved ejection fraction and specific 
clinical profiles (ejection fraction < 57% and female gender) in whom evidence-based heart 
failure therapy is not available [7].
At the time of inclusion, the lowest dose of sacubitril/valsartan was used due to the 
presence of stage G3a renal failure [acc. to Kidney Disease: Improving Global Outcomes 
(KDIGO)]. Dose escalation was abandoned because the patient maintained a trend towards 
low blood pressure (systolic 100–110 mm Hg) and his estimated glomerular filtration rate 
(eGFR) remained stable.
Additionally, we present a safe option to include ARNI as part of outpatient cardiac 
rehabilitation. Inclusion of this group of drugs during cardiac rehabilitation also enables 
proper optimization of pharmacological treatment with other cardiological drugs 
(modification of beta-blocker or diuretic dose).
Streszczenie
W artykule przedstawiono przypadek włączenia sakubitrilu/walsartanu w ramach 
ambulatoryjnej rehabilitacji kardiologicznej u pacjenta z zastoinową niewydolnością serca. 
Przypadek ukazuje, że poza zastosowaniem szpitalnym warto rozważyć włączenie tego leku 
podczas programu ambulatoryjnej rehabilitacji kardiologicznej, gdyż w takich warunkach 
pacjent pozostaje w częstym kontakcie z ośrodkiem prowadzącym leczenie i może podlegać 
niemal codziennej ocenie stanu zdrowia.
Słowa kluczowe: sakubitril, walsartan, ARNI, niewydolność serca, rehabilitacja 
kardiologiczna
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